GlassScriptPhysician profile
Jaafer Imam
NPI 1902216583
$2,495.74
in general payments reported to CMS, 2019-2025
20 companies · $78.63 in 2025
The $78.63 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $114 · 2021: $376 · 2022: $789 · 2023: $778 · 2024: $259 · 2025: $78.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $507.89 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Intuitive Surgical, INC. | $403.52 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $374.06 | 2020-2024 | Tezspire, Airsupra |
| Mylan Specialty L.P. | $178.23 | 2020-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.30 | 2020-2023 | Ofev |
| Regeneron Healthcare Solutions, INC. | $157.75 | 2022-2023 | Dupixent |
| Philips North America LLC | $119.80 | 2020-2022 | |
| Electromed, INC. | $110.85 | 2021-2022 | |
| Genentech USA, INC. | $99.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $85.03 | 2020-2022 | |
| Tactile Systems Technology INC | $52.67 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Actelion Pharmaceuticals US, INC. | $49.37 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $38.93 | 2021-2023 | Airduo Digihaler |
| Insmed, INC. | $36.41 | 2022-2023 | Arikayce |
| United Therapeutics Corporation | $26.15 | 2021-2023 | Tyvaso |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $25.35 | 2023 | Impella |
| Genzyme Corporation | $21.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.50 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.95 | 2022 | |
| Abbvie INC. | $14.49 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaafer Imam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.